

Amendments to the Claims

1-39 (Cancelled)

40. (Currently amended) A method of inducing apoptosis comprising administering an apoptosis inducing agent which comprises isolated glycerolipid as the effective component, to an individual, wherein the fatty acid(s) which constitute said glycerolipid is(are) selected from the group consisting of tetradecanoic acid, hexadecanoic acid, tetradecenoic acid, hexadecenoic acid, octadecenoic acid, cis-9, cis-12-octadecadienoic acid and 9,12,15-octadecatrienoic acid.

41. (Previously amended) The method as set forth in claim 40, wherein said isolated glycerolipid is derived from plants, microorganisms or animals.

42. (Previously amended) The method as set forth in claim 41, wherein said isolated glycerolipid is derived from tea, mushrooms, algae or cereal residues.

43. (Previously amended) The method as set forth in claim 41, wherein said isolated glycerolipid is extracted from plants, microorganisms or animals with an organic solvent.

44. (Previously amended) The method as set forth in claim 43, wherein said isolated glycerolipid is treated with an acid or an alkali prior to extraction.

45. (Previously amended) The method as set forth in claim 43, wherein said isolated glycerolipid is purified by hydrophobic, reversed phase, or normal phase chromatography.

46. (Previously amended) The method as set forth in claim 43, wherein said isolated glycerolipid is extracted from tea, mushrooms, algae or cereal residues.

47. (Previously amended) The method as set forth in claim 40, wherein said isolated glycerolipid consists of fatty acid and glycerol.